BÜHLMANN Laboratories AG Announces Worldwide Collaboration with Beckman Coulter for BUHLMANN fCAL® turbo and fPELA® turbo Assays
BÜHLMANN Laboratories AG, a leading manufacturer of specialty, high-quality in-vitro diagnostic and research assays, is pleased to announce the collaboration with Beckman Coulter for a worldwide distribution of the BÜHLMANN fCAL® turbo assay & BÜHLMANN fPELA® turbo assay... - September 26, 2024
BÜHLMANN Laboratories AG Launches New fPELA® turbo Automated, Random Access Pancreatic Elastase Test
BÜHLMANN fPELA® turbo (FDA Exempt. For in vitro Diagnostic Use) is an in vitro diagnostic assay intended for the quantitation of pancreatic elastase in human stool, is now commercially available in the US. - June 24, 2020
BÜHLMANN Laboratories AG Receives FDA Clearance for CALEX® Cap Fecal Calprotectin Extraction Device
BÜHLMANN CALEX® Cap, a single use tube intended for the preparation of human stool samples to be used with the BÜHLMANN fCAL® turbo, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. - September 25, 2019
BÜHLMANN Laboratories AG Receives FDA Clearance for Its fCAL® turbo Automated, Random Access Calprotectin Test
BÜHLMANN fCAL® turbo, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. - June 27, 2019
BUHLMANN Diagnostics Corp. Announces New Distribution Agreement with Meridian Biosciences, Inc.
BUHLMANN Diagnostics Corp. has embarked on a new partnership with Meridian Bioscience, Inc. for the distribution of the 510(k) cleared, BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool. - January 31, 2019
BÜHLMANN Laboratories AG Receives FDA Clearance for Its fCAL® ELISA Calprotectin Test
BÜHLMANN fCAL® ELISA, an in vitro diagnostic assay intended for the quantitation of calprotectin in human stool, has received 510(k) clearance from the Food and Drug Administration (FDA) and is now commercially available in the US. - June 14, 2018
BÜHLMANN Laboratories AG Announces New Health Canada Licences for Quantum Blue® Infliximab Assay, IBDoc®, and CALEX® Cap Device
BÜHLMANN Laboratories AG’s Quantum Blue® Infliximab, lateral flow assay for rapid quantification of Infliximab in Serum; IBDoc®, the first in-vitro diagnostic home testing device measuring the inflammatory marker fecal calprotectin at home; as well as CALEX® Cap Device for rapid stool extraction are now commercially available in Canada and are Health Canada licenced. - May 02, 2017
BÜHLMANN Laboratories AG Announces New Health Canada License for the BÜHLMANN fCAL® turbo Assay
BÜHLMANN Laboratories AG's immunoturbidimetric assay for fecal calprotectin quantification, BÜHLMANN fCAL® turbo is now commercially available in Canada and is Health Canada licensed. - May 24, 2016
BÜHLMANN Laboratories Opens North American Affiliate
BÜHLMANN Laboratories is proud to announce the availability of its products directly from its new North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire. - January 11, 2016
BUHLMANN Laboratories Announces New, Direct US Affiliate
BÜHLMANN Laboratories is proud to announce the establishment of its North American affiliate, BUHLMANN Diagnostics Corp (BDC) in Southern New Hampshire. - November 16, 2015